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Abstract
Clinical islet transplantation is a promising treatment for patients with type 1 diabetes. However, pancreatic islets vary in size and shape affect-
ing their survival and function after transplantation because of mass transport limitations. To reduce diffusion restrictions and improve islet cell
survival, the generation of islets with optimal dimensions by dispersion followed by reassembly of islet cells, can help limit the length of diffu-
sion pathways. This study describes a microwell platform that supports the controlled and reproducible production of three-dimensional pan-
creatic cell clusters of human donor islets. We observed that primary human islet cell aggregates with a diameter of 100–150 lm consisting of
about 1000 cells best resembled intact pancreatic islets as they showed low apoptotic cell death (<2%), comparable glucose-responsiveness
and increasing PDX1, MAFA and INSULIN gene expression with increasing aggregate size. The re-associated human islet cells showed an a-typ-
ical core shell configuration with beta cells predominantly on the outside unlike human islets, which became more randomized after implanta-
tion similar to native human islets. After transplantation of these islet cell aggregates under the kidney capsule of immunodeficient mice, human
C-peptide was detected in the serum indicating that beta cells retained their endocrine function similar to human islets. The agarose microwell
platform was shown to be an easy and very reproducible method to aggregate pancreatic islet cells with high accuracy providing a reliable tool
to study cell–cell interactions between insuloma and/or primary islet cells.
Keywords: pseudoislets bioengineering beta cells islets type 1 diabetes
Introduction
Although allogeneic islet transplantation offers a promising therapy
for patients with type 1 diabetes, this method is still inefficient
because of considerable islet loss shortly after transplantation
[1, 2]. Upon isolation, the main islet vasculature is damaged or
destroyed. Therefore, mass transport of relevant nutrients mainly
depends on passive diffusion, which adversely affects the viability
of isolated human islets [3]. There are indications that small pancre-
atic islets (≤150 lm), of both human and rodent origin are superior
to larger sized islets in terms of survival and insulin secretion since
they are less susceptible to central necrosis [4–6]. In a study on rat
islet cell aggregates used for microencapsulation the authors
showed that smaller aggregates (≤50 lm) performed better than
native islets in terms of survival and function [5]. Interestingly when
theoretical modelling is used to describe the optimal size for islets,
based on oxygen consumption rate and nutrient diffusion through-
out the islets it was found that a diameter of 100 lm is most
optimal, while in fact native islets range from 50 to 400 lm and
are often not spheroidal shaped [7]. Generation of human islets with
optimal dimensions by islet dispersion and subsequent reassembly
of single islet cells into three-dimensional aggregates, so called
‘pseudoislets’, of a specific dimension may have beneficial effects
on islet survival after transplantation and could help overcome
nutrient diffusion limitations.
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The creation of pseudoislets in which islets cells are assembled in
a three-dimensional configuration may be equally important since
several authors have demonstrated that beta cells require cell–cell
contact to survive and properly function in vitro. The viability of MIN6
cells has been shown to improve when these cells were cultured in
close contact with each other [8]. Moreover, insulin secretion from
these cells had clearly increased in three-dimensional cell aggregates
compared to two-dimensional monolayer cultures [9]. Improvement
of insulin secretion is lost when such cell clusters are dispersed, and
is regained upon re-aggregation [9–11]. Similar results were obtained
when using primary islet cells of both rodent and human origin,
stressing the importance of cell–cell interactions and three-dimen-
sional culture for islet function [12– 15].
The most commonly used technique for creating three-dimen-
sional cell aggregates are static suspension cultures on ultra-low
attachment tissue culture plastic, resulting in a heterogeneous aggre-
gate population with a large variety in aggregate dimensions and
number of cells per aggregate. Another conventional method for cell
aggregation involves the hanging drop method that is normally used
for embryoid body formation when using embryonic stem cells, and
has also been used for the generation of pseudoislets from dispersed
pancreatic rat islets [16–18]. Although the latter technique generates
uniformly sized aggregates, the method is labour-intensive and there-
fore upscaling is limited. Several groups are developing alternative
methods for controlled cell aggregation. Mendelsohn et al. showed
the use of microcontact printing to form multilayered beta cell clus-
ters on laminin-patterned surfaces [19, 20]. Although aggregate size
can be controlled in this way, the cell clusters produced are only a
few cell layers thick and cannot be removed from the substrate for
further research or implantation afterwards. More recently, several
microwell platforms have been developed and applied for controlled
aggregation of various cell types such as embryonic stem cells [21,
22], fibroblasts [23], and chondrocytes [24] in a high-throughput
manner. Recent studies have demonstrated the use of microwells for
the controlled aggregation of MIN6 mouse beta cells, pancreatic pro-
genitor cells, and dispersed rat islets of Langerhans [25–27]. How-
ever until now, controlled aggregation of dispersed human islet cells
to create islets with optimal dimensions has not yet been reported
using aforementioned systems.
Our study describes a high-throughput microwell platform opti-
mized for the generation of stable and uniformly sized aggregates of
human islet cells, which serves two main purposes. First, the platform
supports the formation of three-dimensional clusters of beta cells c
and dissociated human islets, of pre-defined dimensions while provid-
ing the cell-to-cell interaction that is required for these cells to survive
and function properly. Secondly, controlling aggregate dimensions
could help to reduce islet cell death and increase the reproducibility of
experimental results since aggregates of equal size comprising an
equal number of cells can be produced very accurately in high quanti-
ties. We hypothesize that there is an optimal aggregate size and cell
number for three-dimensional assembly of human islet cells. Here, we
report on the creation of primary human islet cell aggregates, pseu-
doislets, with various pre-defined dimensions and the evaluation of
their viability and insulin secretion function. We investigated glucose-
stimulated insulin expression, gene expression of beta cell specific
markers in relation to size and cell number, and studied changes in
morphology and the production of human C-peptide after transplanta-
tion of these human pseudoislets under the kidney capsule of mice.
Materials and methods
Insulinoma cell culture
MIN6 clone B1 mouse insulinoma cells (kindly provided by Dr. P. Hal-
ban, University Medical Center, Geneva, Switzerland) [28] were cultured
in high-glucose DMEM with 2.5 mM L-glutamine (Invitrogen, Bleiswijk,
the Netherlands) supplemented with 10% FBS=fetal bovine serum,
100 U/ml streptomycin, 100 lg/ml penicillin and 70 lM freshly added
beta-mercaptoethanol. INS-1E rat insulinoma cells (kindly provided by
Dr. B. Guigas, LUMC, Leiden, The Netherlands and Dr. P. Maechler,
University Medical Center, Geneva, Switzerland) [29] were cultured in
RPMI with 2.05 mM L-glutamine (Invitrogen) supplemented with 5%
FBS, 100 U/ml streptomycin, 100 lg/ml penicillin, 10 mM HEPES,
1 mM sodium pyruvate, 50 lM freshly added beta-mercaptoethanol.
Cell cultures were maintained at 37°C in humidified air containing 5%
carbon dioxide. Medium was refreshed every 3–4 days and cells were
replated when 80% confluency was reached.
Primary human islet culture
Human islets of Langerhans not used for clinical islet transplantation were
provided by the Leiden University Medical Center, Leiden, The Nether-
lands. Organs donors (4M/6F) had an average age of 50  13 years and
BMI of 23  3 kg/m2 (Fig. S1). Islets were dispersed into single cells by
adding 0.025% trypsin solution containing 10 lg/ml DNase (Pulmozyme,
Genentech, San Francisco, CA, USA) and seeded onto agarose microwells
for controlled cell aggregation. Intact islets and human islet cell aggre-
gates were cultured in CMRL 1066 medium (5.5 mM glucose) (Media-
tech, Manassas, VA, USA) supplemented with 10% foetal calf serum,
20 lg/ml ciprofloxacin, 50 lg/ml gentamycin, 2 mM L-glutamine,
0.25 lg/ml fungizone, 10 mM HEPES and 1.2 mg/ml nicotinamide. Cell
cultures were maintained at 37°C in a 5% CO2 humidified atmosphere.
Medium was refreshed every 3–4 days.
Agarose microwell fabrication and cell aggregate
formation
Non-adherent agarose microwells were aseptically fabricated as described
previously [30]. Briefly, microwell chips containing 2865 microwells with
a diameter of 200 lm and chips containing 1585 microwells with a diam-
eter of 400 lm were fabricated by pouring a 3% (w/v) UltrapureTM agarose
(Invitrogen, Bleiswijk, the Netherlands) solution on negative moulds of
polydimethylsiloxane (PDMS). After agarose solidification, the moulds
were removed, covered with PBS and stored at 4°C until usage (see
Fig. 1). Before cell seeding, the agarose chips were pre-incubated in cul-
ture medium overnight at 37°C. For cell aggregate formation, single cells
were resuspended in fresh medium and seeded onto agarose chips at var-
ious densities resulting in aggregates consisting of 10, 25, 50, 100, 250,
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500 and 1000 cells. Immediately after seeding, agarose chips were briefly
centrifuged at 300 9 g to allow the cells to settle down in the microwells.
As a control, 1 9 105 cells were seeded onto ultra-low attachment plastic
to allow spontaneous cell aggregation. Medium was refreshed every 1–
2 days. Cell aggregates were cultured up to 7 days after which they were
removed from the chips by upside down centrifugation (1 min. at
300 9 g) or by medium flush, and used for further analysis. To measure
the average aggregate diameter, microscopic images were taken and
aggregate diameter was quantified using ImageJ (NIH image). For INS-1E
cell aggregates, at least 50 aggregates were measured. For human islet
cell aggregates, at least 40 aggregates derived from islet preparations of
three different human donors were analysed.
Scanning electron microscopy
INS-1E cell aggregates were flushed out of the microwells, fixed in 4%
(w/v) paraformaldehyde and embedded by mixing in 2% (w/v) agarose.
Samples were prepared for scanning electron microscopy by dehydra-
tion in increasing concentrations of ethanol (1 hr each step) and dried
using critical point dryer equipment (CPD 030; BAL-TECBalzers, Liech-
tenstein). The samples were sputter-coated with gold and imaged using
a scanning electron microscope (XL30 ESEM-FEG, Philips, Eindhoven,
the Netherlands).
Cell viability
Cell viability was assessed on day 7 by staining the cells with 6 lM
ethidium homodimer and 1 lM calcein using a LIVE/DEAD Viability/Tox-
icity Kit (Invitrogen, NL) and visualized using fluorescence microscopy
(Nikon Eclipse E600, NIKON, Amsterdam, the Netherlands). Viable cells
were stained green, and DNA of dead cells was stained red. Staining
was quantified as percentage of viable cells per total cell number,
counting at least 100 cells per condition.
Histological analysis
Human islets, human islet cell aggregates and INS-1E cell aggregates
were fixed in 4% (w/v) paraformaldehyde, washed in PBS, dehydrated
in ethanol series, embedded in paraffin, and sectioned at 4–5 lm using
a microtome (Microm HM355S; Thermo Scientific, Breda, the Nether-
lands). Sections were deparaffinized in xylene, rehydrated in decreasing
concentrations of ethanol (100–96–90–80–70%) and rinsed in H2O and
PBS.
For immunohistochemical labelling of insulin, blocking was done
using dual endogenous enzyme block (DAKO, Glostrup,Denmark). Sec-
tions were incubated with rabbit anti-human insulin polyclonal antibody
(1:400; Santa Cruz Biotechnology, Inc, Heidelberg, Germany for 1 hr at
21°C, followed by subsequent washing steps in PBS and 1% (v/v)
bovine serum albumin/PBS and incubated with HRP-goat anti-rabbit IgG
secondary antibody (1:100; DAKO, Glostrup Denmark) for 1 hr at 21°C.
Sections were then rinsed in PBS and incubated for 4 min. with DAB
liquid chromogen system (DAKO, Glostrup, Denmark), which yields a
brown colour. Counterstaining was performed with haematoxylin (Gill’s
haematoxylin no. 3, Sigma-Aldrich, Zwijndrecht, the Netherlands)
according to the manufacturer’s protocol and samples were visualized
using a Nikon Eclipse E600 microscope.
For fluorescent immunolabelling of insulin and glucagon, blocking was
done with 0.1% (w/v) normal donkey serum/PBS for 1 hr and antibodies
were diluted in 1% (v/v) lamb serum/PBS. Primary antibodies used were:
1:100 rabbit-anti-glucagon (Vector Labs Amsterdam, the Netherlands)
overnight at 4°C, and 1:200 guinea pig-anti-insulin (Abcam) for 1.5 hrs at
21°C. Secondary antibodies used were: 1:200 biotin donkey anti-rabbit
(Jackson ImmunoResearch), 1:200 streptavidin-Alexa488 Invitrogen, NL
1:400 rhodamine donkey anti-guinea pig (Jackson ImmunoResearch Suf-
folk, United Kingdom), all incubated for 1 hr at 21°C. Counterstaining was
performed with 1 lg/ml 40-6-diamidino-2-phenylindole. Fluorescence
was visualized using a Nikon Eclipse E600 microscope.
Apoptosis was assessed by TUNEL assay Roche, Woerden, the Neth-
erlands. Sections were examined using confocal microscopy. The num-
ber of stained cells was quantified and expressed as percentage of
positive cells per total cell number, counting at least 750 cells per
donor for each condition.
Glucose-stimulated insulin secretion test
To test insulin secretory capacity, three groups of 50 human islets,
human islet cell aggregates or INS-1E cell aggregates were hand-picked,
transferred to an ultra-low attachment plate and incubated in a modified
Krebs-Ringer bicarbonate buffer.
Fig. 1 Schematic representation of aga-
rose microwell fabrication and cell
aggregation.
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INS-1E cell aggregates were pre-incubated for 2 hrs in glucose-free
culture medium, followed by a 30 min. pre-incubation in glucose-free
incubation buffer. Subsequently, the INS-1E cell aggregates were
incubated during three consecutive steps of 30 min. in low glucose buf-
fer (2 mM), high-glucose buffer (20 mM) and low glucose buffer
(2 mM) at 37°C. Human islets and human islet cell aggregates were
pre-incubated for 1.5 hrs in glucose-free buffer followed by three suc-
cessive incubation steps of 1 hr in low-glucose buffer (2 mM), high-
glucose buffer (20 mM) and low-glucose buffer (2 mM) at 37°C. Perifu-
sion experiments were performed in a similar order using Suprafusion
1000 ( Brandel, UK) at a flow of 0.2 ml/min., obtaining samples every
7.5 min. Islets and islet cell aggregates were sequentially incubated in
low glucose (2 mM, samples 1–2), high glucose (20 mM, samples 3–
10), and low glucose (2 mM, samples 11–20). Fold induction was
expressed relative to the average value at the end of the lead-in period
as base reference.
Medium samples were collected and the amount of secreted insulin
was determined by ELISA according to the manufacturer’s protocol
(Mercodia, Sweden). Absorbance was analysed with Thermo Scientific
Multiscan Go (450 nm). After glucose-stimulated insulin secretion test
(GSIS), aggregates were collected and analysed for total DNA content
using Quant-iT picogreen dsDNA assay kit (Invitrogen, NL). Fluores-
cence was analysed with a Perkin Elmer 1420 Multilabel counter (excita-
tion 480 nm, emission 520 nm). Secreted insulin was normalized to the
total DNA amount. Stimulation index (SI) was calculated as a ratio of
released insulin after high-glucose stimulation divided by released after
low glucose stimulation.
Quantitative PCR
Total RNA was extracted using RNeasy kit Qiagen Benelux BV, Venlo,
the Netherlands according to the manufacturer’s protocol. Total RNA
(1 lg) was reverse transcribed using M-MLV reverse transcriptase
(Invitrogen, Bleiswijk, the Netherlands). Quantitative PCR (qPCR) was
performed with a Light Cycler 480-II Real-time PCR system (Roche,
NL). Fold induction was calculated using deltaCT method with human
b-actin as housekeeping gene.
C-peptide assay
Human C-peptide levels were measured in mouse serum using ultrasen-
sitive C-peptide ELISA (Mercodia, Uppsala, Sweden) according to the
manufacturer’s protocol. Data are represented as average values (SD)
from two donors with 3–5 mice each donor.
Animal transplantation
The Leiden University Medical Center committee for animal ethics
approved all animal experiments. Human islet cell aggregates (from 2
donors) were formed in vitro by 2-day aggregation of 1000 cells per
microwell. Aggregates were harvested from the chips (2865 aggregates
per chip) and transplantation was done with the yield of one chip under
the kidney capsule of 7- to 15-week-old male NOD/SCID mice (n = 3),
NOD.CB17-Prkdcscid/NcrCrl (Charles River, NL). After 14 days, the islet
cell aggregate grafts were removed for histology and immunofluores-
cent labelling.
Statistical analysis
Statistical analyses were performed with one-way ANOVA and Bonferroni
post-test. *P < 0.05, **P < 0.01, ***P < 0.001.
Results
Fabrication and validation of microwell platform
for controlled cell aggregation
Agarose microwell chips were fabricated using PDMS moulds. The
chips are compatible with standard 12-well cell culture plates and
contain 2865 non-adherent microwells with a diameter of 200 lm
(Fig. 2A). When a single cell suspension is seeded onto these chips,
controlled aggregation is induced and stable cell clusters are formed,
as schematically shown in Figure 2B. To visualize cell aggregation
inside these microwells, we measured the aggregate diameter of INS-
1E cell aggregates in time. Figure 2C shows that single INS-1E cells
started forming aggregates during the first 2 days of culture after
which the aggregates remained stable in size until the end of the
7 days culture period. In addition, scanning electron microscopy
demonstrated that the INS-1E cell aggregates do not disintegrate dur-
ing harvesting from the chip, or during 7 days of suspension culture
subsequently indicating solid integrity (Fig. 2D). INS-1E cell aggre-
gates obtained by conventional suspension culture on ultra-low
attachment plates showed a large size distribution with an average
aggregate diameter of 88  49 lm, whereas controlled aggregation
of 500 cells per well in our microwell platform resulted in uniformly
sized aggregates of 93 lm (SD  16; Fig. 2E).
Controlled generation of insulinoma and primary
human islet cell aggregates
Controlled aggregation using these microwells was further optimized
using MIN6 clone B1 and INS-1E insulinoma cell lines. These insulin-
producing cell lines are widely used as a model for primary beta cells
since they resemble most native beta cells [31, 32]. Cells were seeded
onto microwell chips at various densities to generate aggregates of
10, 25, 50, 100, 250 and 500 cells, resulting in aggregates with well-
defined dimensions. The aggregates could easily be removed from
the chips by flushing out and mild centrifugation (Fig. 3A), after
which they were used for further analysis. The average aggregate
diameter correlates with the initial number of cells seeded per micro-
well , which ranged between 29 and 105 lm for INS-1E cells, and
between 28 and 93 lm for MIN6 clone B1 cells, as shown in Fig-
ure 3B. Increasing the number of cells per microwell to 1000
resulted in unstable cell aggregates that were not suitable for further
use. Next to controlled aggregation of MIN6 and INS-1E cell lines, our
microwell platform supports the controlled reassembly of primary
human islet cells. Human donor islets of Langerhans were dissociated
into a single cell suspension (>95% viability, data not shown) and
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seeded at 100, 500 and 1000 cells per microwell to induce controlled
aggregation similar to the insuloma cell lines. The resulting primary
islet cell aggregates were uniform in size and remained intact after
harvesting from the chips (Fig. 3C). After 7 days of culture, the islet
cell aggregates had an average diameter of 80  5.4, 105  11.3
and 134  15.3 lm respectively, depending on the initial cell num-
ber seeded (Fig. 3D). To study cell assembly kinetics, representative
images were taken at different time-points during aggregate forma-
tion. We observed that aggregation occurs in the first 2–4 days after
cell seeding, and stable aggregates are obtained after 7–14 days of
culture (Fig. S2). Since 200 lm diameter microwells cannot contain
more than 1000 cells, we created wells with a diameter of 400 lm.
Increasing the cell seeding density in these microwells to 2000, we
observed that islet cells assembled uncontrollably into multiple smal-
ler aggregates per well.
INS-1E insulinoma cell aggregates are viable
and functional
To assess basic cell function within the aggregates in more detail,
INS-1E cell aggregates were cultured in the agarose microwell plat-
form up to 7 days after which cell viability, protein expression and
insulin secretion was assessed. Live/dead staining was performed on
cells inside the microwell array and demonstrated a cell viability of at
least 80% for all aggregate sizes (Fig. 4A). Insulin-specific immunola-
belling showed that INS-1E cell aggregates of various sizes consisting
of 50, 100 and 500 cells still expressed insulin (Fig. 4B). To test glu-
cose-responsiveness, the aggregates were challenged with a high-
glucose concentration. The INS-1E cell aggregates secreted insulin
upon a high-glucose stimulus, and insulin secretion returned to base-
line after a second stimulation with low glucose. Aggregates of vari-
ous sizes all responded in the same way (average SI = 1.86  0.7)
(Fig. 4C).
Primary human islet cell aggregates are viable
and functional in vitro
Human islet cell aggregates of various sizes were assessed for
morphology, beta cell apoptosis, gene and protein expression and
insulin secretion function. The a-typical architecture, with gluca-
gon-positive alpha cells located in the core, and insulin-positive
beta cells at the periphery of aggregates that was previously pub-
lished by our group [33], was present in both small (250 cells)
and in large (1000 cells) human islet cell aggregates (Fig. 5A).
TUNEL-insulin double staining showed few apoptotic cells, which
comprise mainly non-beta cells (Fig. 5B). Quantification of TUN-
EL+ cells showed less than 2.5% overall cell apoptosis for small
aggregates (100–250 cells) and less than 1% apoptotic cell death
for aggregates consisting of 500 or 1000 human islet cells
(Fig. 5C). We measured the gene expression for INSULIN, MAFA
and PDX1 at day 7 of culture. The expression levels in human




Fig. 2 Fabrication and validation of a microwell platform for controlled production of uniformly sized aggregates. (A) Agarose microwell chip contain-
ing 2865 non-adherent wells with a diameter of 200 lm. (B) Schematic representation of controlled cell aggregation in agarose microwell chips.
Single cells are seeded in suspension onto agarose microwell chips and briefly centrifuged to allow the cells to settle down in the microwells (T0).
In time, cells assemble and stable cell clusters are formed (T1). (C) INS-1E cell aggregate formation in agarose microwells. Single INS-1E cells
aggregate in the first 2 days of culture and form stable aggregates that were maintained up to 7 days of culture. (D) SEM image of an INS-1E cell
aggregate that was embedded in agarose gel; scale bar = 50 lm. (E) The microwell platform generates uniformly sized INS-1E cell aggregates with
less variability (SD = 16) compared to conventional suspension culture (SD = 49; n = 100).
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of the same donor. However, we found that increasing the num-
ber of cells per aggregate from 100 to 1000 lead to increased
expression of INSULIN, PDX1 and MAFA, which was still some-
what lower compared to intact cultured islets of the same origin
(Fig. S3). Importantly, glucose-stimulated insulin secretion assays
demonstrated that primary human islet cell aggregates of 250 and
1000 cells responded similar to high-glucose as intact control
islets of the same donor after 7 days of culture (Fig. 5D). No sig-
nificant differences were observed between the stimulation indices
of primary human islet cell aggregates of 250 or 1000 cells
(SI = 2.1 and 1.8, respectively), and intact control islets
(SI = 2.3) of the same donor. Similar results were obtained after
dynamic GSIS. Although dynamic GSIS showed a more sustained
secretion during high glucose in intact islets compared to aggre-
gates, stimulation indices were found to be similar with some
variation between the two donors (Fig. 5E).
Primary human islet cell aggregates are viable
and functional in vivo
Following 2 days of in vitro aggregation in microwells primary human
islet cell aggregates were transplanted for 14 days under the kidney
capsule of NOD/SCID mice. Figure 6A shows that after 14 days in
vivo, human islet cell aggregates exhibit a normal cellular architec-
ture. Quantification of TUNEL+ cells showed negligible,
0.95  0.75%, apoptotic cell death. Human C-peptide, around
200 pmol/l (average of 2 human donors) at day 7 and 14, was
observed in serum of transplanted mice whereas the human C-pep-
tide concentrations in non-transplanted mice were undetectable at
day 7 and 14 post transplantation (Fig. 6B).
Discussion
The controlled assembly of primary human islet cells into pre-
defined three-dimensional optimal aggregates, in which beta cells
show appropriate endocrine function, may have beneficial effects
on islet survival after transplantation and could help overcome
nutrient diffusion limitations. We developed a microwell platform
for the generation of human islet cell aggregates of pre-defined
dimensions comprising equal cell numbers. We studied the con-
trolled formation of primary human islet cell aggregates and
investigated morphology, the apoptotic cell death and beta cell
function in relation to their size. Human islet cell aggregates with
a diameter of 100–150 lm showed little apoptotic cell death
A B
C D
Fig. 3 Seeding density determines aggregate size of insulinoma and human islet cell aggregates. (A) INS-1E cell aggregates of 50, 100, and 500
cells after 7 days of culture inside agarose microwells (top panel) and after flushing out of the chip (bottom panel); scale bar = 200 lm. (B) Corre-
lation between number of INS-1E and MIN6 cells per microwell and diameter of obtained aggregates after 7 days of culture. INS-1E and MIN6 cells
were seeded at 10, 25, 50, 100, 250 and 500 cells per microwell. Each datapoint represents the average measurement of at least 50 aggregates per
condition; error bars represent SD. (C) Primary human islets were dispersed and single islet cells were seeded at 100, 500 and 1000 cells per mi-
crowell. Figures represent human islet cell aggregates inside the microwells (top panel) and after flushing them out of the chip (bottom panel) after
7 days of culture; scale bar = 200 lm. (D) The diameter of human islet cell aggregates increased with increasing the number of cells seeded per
well. Cells were seeded at 100, 500 and 1000 cells per microwell. At least 40 human islet cell aggregates were measured per condition. Data points
represent the average values for three human donors; error bars represent SD.
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(<2%), an adequate insulin secretory response to a glucose, and
MAFA, PDX1 and INSULIN gene expression similar to human
islets. After reassociation of the primary human islet cells the
aggregates constituted a specific core and mantle arrangement, in
which the mantle comprised predominantly of beta, and the core
of alpha cells, which is a-typical compared to the native random
dispersion normally found in human islets. These findings confirm
our previous observations in a recent study on beta to alpha cell
transdifferentiation in which a similar observation was done [33].
Others have demonstrated that dispersed rat islet cells reassemble
in culture and form islet-like aggregates with a core mantle orga-
nization similar to that of native rodent islets, which indicates that
the signals required for this specific organization are likely cell-
mediated [34]. It has been shown that differential expression of
distinct cell adhesion molecules (CAMs), more specifically neural
CAM (N-CAM), is responsible for the establishment and mainte-
nance of rat islet architecture [35–37]. Our findings suggest that
in contrast to rodent islet cells, the islet cells themselves do not
solely mediate the unique cellular organization of human islets.
Despite their non-native architecture, the in vitro insulin secretory
response of human islet cell aggregates of various sizes suggests
that islet dispersion and reassembly does not affect their glucose-
responsiveness.
We found that in vivo transplantation of primary human islet
cell aggregates for 14 days under the kidney capsule of NOD/CID




Fig. 4 INS-1E cell aggregates of various
sizes remain viable and functional up to
7 days of culture. (A) INS-1E cell aggre-
gates were formed using agarose micro-
wells. After 7 days of culture, a viability
assay was performed to visualize living
cells (green) and dead cells (red). (B) His-
tological evaluation of INS-1E cell aggre-
gates of 50, 100 and 500 cells after
7 days of culture. Both DAB chromogen
and fluorescent anti-insulin staining dem-
onstrate that INS-1E cell aggregates of
various sizes express insulin; scale
bars = 50 lm. (C) Glucose-stimulated
insulin secretion of INS-1E cell aggregates
of various sizes measured after 7 days of
culture (100 aggregates per condition, in
triplicate); error bars represent SD.
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become more heterogeneously distributed throughout the islet
graft, like is found in normal human islets, suggesting that exter-
nal factors like revascularization, or cell-matrix interactions are
involved in maintaining normal islet architecture and responsible
for remodelling of the initial core mantle distribution observed.
The trigger to induce migration could be the change in oxygen
tension and nutrient availability because of in vivo re-vasculariza-
tion, while in vitro the nutrient supply is solely dependent on
mass transport by diffusion to the cells in the aggregate. The
latter could mean that the cells in the aggregate core are
exposed to less than optimal nutrient and oxygen supply. The
second possibility for in vivo aggregate remodelling is that cells
can transdifferentiate, and therefore grafts change to a different





Fig. 5 Human islet cell aggregates are viable and function in vitro. (A) Human islet cell aggregates of all sizes show an architecture with beta cells
(red) located at the periphery and alpha cells (green) in the core. In comparison, intact human islets show a heterogeneous distribution of alpha-
and beta cells. (B) TUNEL staining showing only few apoptotic cells in both small (250 cells/aggregate) and large (1000 cells/aggregate) human islet
cells aggregates (positive cells are indicated with an arrow). (C) Quantification of TUNEL+ cells shows that 2.5% of all cells are apoptotic in small
aggregates. Aggregates of 500 or 1000 cells contain less than 1% apoptotic cells (n = 3–4 donors per condition). (D) Static glucose-stimulated
insulin secretion (GSIS) test was performed on human islet cell aggregates of 250 and 1000 cells and compared with intact control islets. Islet cell
aggregates of both sizes show a similar secretory response as intact control islets; error bars represent SD. (E) Dynamic GSIS shows more sus-
tained insulin secretion during high glucose in intact islets compared to human islet cell aggregates, although the induction is similar; scale
bar = 100 lm.
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age tracing techniques that can trace a-cell fate available. We
cannot therefor exclude, or support the hypothesis of a-cell to
b-cell conversion. Although we have recently shown that b-cells
can convert into a-cells in this relatively short time period, we
do not see an increased percentage of b-cells in our grafts, sug-
gesting migration is a more likely event [33].
Controlled cell aggregation in our microwell platform was opti-
mized using MIN6 and INS-1E cell lines and resulted in uniformly
sized cell aggregates with a small variability in diameter, compared to
heterogeneous cell aggregation in conventional suspension culture.
Using our microwells, aggregate dimensions could accurately be
controlled by changing the initial cell seeding density, resulting in
cell aggregates with pre-defined dimensions. This is in line with
other studies demonstrating the use of poly(ethylene glycol) micro-
wells for controlled aggregation of MIN6 beta cells and the aggre-
gation of dispersed rat islet cells in glass micromoulds [25, 27].
Our wells were prepared in agarose, which is a polysaccharide that
is cheap, non-toxic and easy to use. In addition, cells do not
adhere to the material that supports cell aggregation. Since no spe-
cial equipment is required, the microwells can be used in all basic
research laboratories in standard tissue culture plates. In addition,
the negative PDMS moulds can easily be varied to create micro-
wells of various sizes and shapes, and are re-usable which makes
for a fast and sustainable low-cost and reliable fabrication proce-
dure. The maximum aggregate diameter that could be obtained
using our platform was limited to approximately 150 lm, as
increasing the number of cells above 1000 cells per aggregate
resulted in unstable aggregates. We find that controlling cell aggre-
gation using this microwell platform aids in reducing the variability
and increases the reproducibility of experimental results, since it
allows one to accurately control aggregate size by seeding a spe-
cific cell number per well. A major advantage of the agarose micro-
well cell aggregation method compared to conventional ultra-low
attachment plates is the reproducibility of aggregate formation.
Whereas cell aggregation in ultra-low attachment plates, as shown
in Figure 2, results in aggregates, with heterogeneous size and
shape between 40 and 250 lm, while aggregation in the agarose
microwell system results in well-defined aggregates, between 90
and 110 lm ensuring reproducible results when comparing differ-
ent conditions and repetitive experiments. In comparison to, for
example, the more labour-intensive hanging drop method; the aga-
rose microwell technique consists of a high-throughput format
following standard simple cell culture procedures without the need
for careful handling of samples.
Regarding their endocrine function, INS-1E cell aggregates
showed an insulin secretory response upon stimulation with high glu-
cose, indicating that the aggregates were glucose-responsive. This is
in line with an extensive follow-up study by Merglen et al., reporting
that INS-1E cells and primary rat islets share similar insulin secretory
kinetics, underlining the potential of INS-1E cell aggregates as a
valuable model for research purposes [29]. We did not observe a cor-
relation between aggregate size and function, which is in agreement
with other studies using MIN6 cells [25].
In conclusion, our agarose microwell platform provides a plat-
form to create primary human islet cell aggregates, pseudoislets,
with pre-defined dimensions. This three-dimensional shape has
been shown to be critical for optimal beta cell function [38]. We
showed that primary human islet cell aggregates with a diameter
of 100–150 lm remain stable, viable and functional both in vitro
and in vivo. We find that controlled reassembly of dissociated
human islet cells into pre-defined aggregates leads to an initial a-
typical core mantle arrangement of beta and alpha cells, which
remodels after implantation under the kidney capsule during
14 days. Moreover, with increase in islet cell number and aggre-
gate diameter beta cell specific gene expression and function
increases to almost similar levels as native islets. The slight differ-
ences between islets cell aggregates and native islets seem to sug-
gest a crucial factor is missing, an important factor could be the
lack of appropriate beta cell and extracellular matrix interaction,
which is known to play an important role in beta cell function, the
cellular interaction with islet extracellular matrix is evidently lost
after enzymatic dissociation of pancreatic islets [39]. Future
research could include the role of islets extracellular matrix pro-
teins and their effect on beta cell function during islet cell aggre-
gate assembly using agarose microwells for controlled aggregation
to further elucidate this finding.
A B
Fig. 6 Human islet cell aggregates are viable and function in vivo. (A) 14 days after transplantation under the kidney capsule of immunodeficient
mice, human islet cell aggregates (1000 cells/aggregate) show a heterogenous cell architecture that is similar to intact human islets, with alpha-
and beta cells randomly spread throughout the aggregate; scale bar = 50 lm. (B) Serum C-peptide levels seem higher in transplanted mice com-
pared to control mice at day 7 and 14 after transplantation (n = 3–5 mice, 2 donors); error bars represent mean  SD.
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